Get all your news in one place.
100's of premium titles.
One app.
Start reading
International Business Times UK
International Business Times UK
Niloy Chakrabarti

Why This Chinese Herbal Medicine Stock Backed by BlackRock and Morgan Stanley Gained 50,000% in 6 Months Despite Posting Losses

Only 30 million of the 500 million RGC shares can be publicly traded. (Credit: Mareefe/Pexels.com)

Shares of Regencell Bioscience (NASDAQ:RGC) gained 49,637% in the past six months despite record losses since going public in 2021. The Chinese medicine company, with shareholders like Digital Mobile Venture, BlackRock, Morgan Stanley, and RBC, went public in 2021. It develops herbal medicine treatments for neurocognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD).

The company posted over £7.4 million ($10 million) in losses in the past two fiscal years. Despite being unprofitable, RGC shares made monumental moves on no major developments or company news, leaving investors confused about investment prospects.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.